Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 - Piccart, M; Hortobagyi, G N; Campone, M; Pritchard, K I; Lebrun, F; Ito, Y; Noguchi, S; Perez, A; Rugo, H S; Deleu, I (Ann Oncol, 2014)
et al.